Download the ESMO 2012 Abstract Book - Oxford Journals

Annals of Oncology
Conclusion: Our findings suggest that early changes on both biomarkers, FMISO
and pVEGFR, with one cycle of bevacizumab alone predict pathological response in
bevacizumab-based neoadjuvant therapy in breast cancer.
Disclosure: All authors have declared no conflicts of interest.
201P PROGNOSTIC VALUE OF KI-67 LABELING INDEX IN
PATIENTS WITH DUCTAL INTRAEPITHELIAL NEOPLASIA OF
THE BREAST. POSTSURGICAL OUTCOME FOR 1171 WOMEN
CARED FOR IN ONE SINGLE INSTITUTION OVER 10 YEARS
M. Lazzeroni 1 , E. Botteri 2 , A. Guerrieri Gonzaga 1 , M.C. Leonardi 3 , D. Serrano 1 ,
A. De Censi 4 , N. Rotmensz 2 , C. Varricchio 1 , B. Bonanni 1 , G. Puneri 5
1 Division of Cancer Prevention and Genetics, European Institute of Oncology,
Milan, ITALY, 2 Division of Epidemiology and Biostatistics, European Institute of
Oncology, Milan, ITALY, 3 Division of Radiotherapy, European Institute of
Oncology, Milan, ITALY, 4 Medical Oncology, E.O. Ospedali Galliera, Genoa,
ITALY, 5 Division of Pathology, European Institute of Oncology, Milan, ITALY
The aim of this analysis was to investigate the prognostic relevance of Ki-67 labeling
index (LI) in patients with Ductal Intraepithelial Neoplasia (DIN) of the breast. From
January 1997 to December 2007, histopathologic and clinical data on 1,171
consecutive patients operated for DIN in a single institution were collected through
the institutional clinical database. The study was performed in accordance with
REMARK criteria. The independent prognostic role of Ki-67 LI was evaluated with a
multivariable Cox regression model. Median age was 52 years, median Ki-67 LI 15%
(range 1-80) and median follow-up was 86 months (range 1-192). A total of 872
(74.5%) patients underwent breast conservative surgery. Whole breast radiotherapy
was administered to 356 patients, and 506 patients received endocrine treatment.
Overall, 549 (46.9%) women were premenopausal at the time of diagnosis. In regard
to histology, most DINs were solid or cribriform (75%), moderately-low differentiated
(80%), with a low proliferating index (Ki-67 LI < 14%, 46%), and with estrogen
receptor positive immunostaining (80%). Overall, ipsilateral recurrence of both
invasive and in situ disease (5-year cumulative incidence) was 163 (10.7%). When
dividing patients into three subgroups on the basis of Ki-67 LI (< 14%, 14-20% and
>20%), the 5-year cumulative incidence of breast recurrences were 9.4%, 10.3%, and
13.0% respectively [Hazard Ratio (HR) 14-20 vs 20 vs 40 pg/ml had improved TTP (328 D; p =
0.01), compared to those with PlGF levels 66.3 pg/ml at D8-56 had improved PFS (p = 0.029) and OS (p =
0.02). In RCC, 5 pts with ΔPlGF below this threshold had median PFS of 100 D
vs 207 D in the remaining pts (p = NS). Across the P2 studies, toxicity
thresholds were determined using PlGF levels at D8 and toxicity events resulting
in dose reductions or interruptions. The efficacy and toxicity thresholds were
used to identify optimal ΔPlGF levels associated with improved OS in HCC (p
= 0.01) and RCC pts (p = 0.001).
Conclusions: Optimal ΔPlGF plasma levels were identified and associated with
improved outcome in HCC and RCC pts receiving linifanib. Monitoring of PlGF
levels may allow clinicians to identify pts with increased sensitivity or toxicity risk on
linifanib. Further evaluation in randomized linifanib studies is warranted, including
dose adjustments based on ΔPlGF levels.
Disclosure: E.M. Mc Keegan: Full time Abbott employee who owns stock. A.
Chakravartty: Full time Abbott employee who owns stock. P.J. Ansell: Full time
Abbott employee who owns stock. S. Datwyler: Full time Abbott employee who owns
stock. M.D. McKee: Full time Abbott employee who owns stock. J.L. Ricker: Full time
Abbott employee who owns stock. D.M. Carlson: Full time Abbott employee who
owns stock. All other authors have declared no conflicts of interest.
Volume 23 | Supplement 9 | September 2012 doi:10.1093/annonc/mds391 | ix83